Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12800, Prague, Czech Republic.
Department of Pathology, Charles University, 3rd Faculty of Medicine, University Hospital Královské Vinohrady, 10034, Prague, Czech Republic.
Diagn Pathol. 2023 Feb 28;18(1):32. doi: 10.1186/s13000-023-01317-9.
We examined a large cohort of serous tubo-ovarian tumors with 26 immunohistochemical markers, with the aim to assess their value for differential diagnosis and prognosis.
Immunohistochemical analyses with 26 immunomarkers were performed on 250 primary tubo-ovarian tumors including 114 high grade serous carcinomas (HGSC), 97 low grade serous carcinomas (LGSC), and 39 serous borderline tumors (micropapillary variant, mSBT). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher's Exact test.
We found significantly different expression of p53, p16, ER, PR, PTEN, PAX2, Mammaglobin, RB1, Cyclin E1, stathmin, LMP2, L1CAM, CD44, and Ki67 in HGSCs compared to LGSCs. No significant differences were found between LGSC and mSBT. None of the other included markers (PAX8, ARID1A, HNF1B, Napsin A, CDX2, SATB2, MUC4, BRG1, AMACR, TTF1, BCOR, NTRK) showed any differences between the investigated serous tumors. Regarding the prognosis, only PR and stathmin showed a statistically significant prognostic meaning in LGSCs, with better overall survival (OS) and recurrence-free survival (RFS) in cases positive for PR, and worse outcome (RFS) for stathmin. None of the study markers showed prognostic significance in HGSCs.
We provided an extensive immunohistochemical analysis of serous ovarian/tubo-ovarian tumors. Although we found some differences in the expression of some markers in HGSCs compared to LGSCs, only p53, p16, and Ki67 seem to be useful in real diagnostic practice. We also suggested the best discriminative cut-off for Ki67 (10% of positive tumor cells) for distinguishing HGSC from LGSC. We found prognostic significance of PR and stathmin in LGSCs. Moreover, the high expression of stathmin could also be of predictive value in ovarian carcinomas as target-specific anti-stathmin effectors are potential therapeutic targets.
我们研究了一组包含 26 种免疫标志物的浆液性卵巢/输卵管肿瘤大样本队列，旨在评估它们在鉴别诊断和预后方面的价值。
对 250 例原发性卵巢输卵管肿瘤进行了 26 种免疫标志物的免疫组化分析，其中包括 114 例高级别浆液性癌（HGSC）、97 例低级别浆液性癌（LGSC）和 39 例浆液性交界性肿瘤（微乳头状变异型，mSBT）。使用卡方检验或 Fisher 确切检验评估总体阳性与临床病理特征的相关性。
我们发现 p53、p16、ER、PR、PTEN、PAX2、Mammaglobin、RB1、Cyclin E1、stathmin、LMP2、L1CAM、CD44 和 Ki67 在 HGSCs 中的表达与 LGSCs 相比存在显著差异。LGSC 和 mSBT 之间无显著差异。所研究的浆液性肿瘤中，其他包括标记物（PAX8、ARID1A、HNF1B、Napsin A、CDX2、SATB2、MUC4、BRG1、AMACR、TTF1、BCOR、NTRK）均无差异。关于预后，仅 PR 和 stathmin 在 LGSCs 中具有统计学意义的预后意义，PR 阳性的总生存率（OS）和无复发生存率（RFS）更好，stathmin 预后更差。研究标记物在 HGSCs 中均无预后意义。
我们对浆液性卵巢/输卵管肿瘤进行了广泛的免疫组化分析。虽然我们发现 HGSCs 与 LGSCs 相比，一些标记物的表达存在差异，但只有 p53、p16 和 Ki67 似乎在实际诊断实践中有帮助。我们还建议 Ki67（阳性肿瘤细胞的 10%）用于区分 HGSC 和 LGSC 的最佳区分性截止值。我们发现 PR 和 stathmin 在 LGSCs 中的预后意义。此外，stathmin 的高表达也可能是卵巢癌的预测价值，因为针对 stathmin 的效应器可能是潜在的治疗靶点。
Zotero 插件
